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ABSTRACT
In this article we draw on the concept of a social licence
to explain public concern at the introduction of care.
data, a recent English initiative designed to extract data
from primary care medical records for commissioning and
other purposes, including research. The concept of a
social licence describes how the expectations of society
regarding some activities may go beyond compliance
with the requirements of formal regulation; those who
do not fulﬁl the conditions for the social licence (even if
formally compliant) may experience ongoing challenge
and contestation. Previous work suggests that people’s
cooperation with speciﬁc research studies depends on
their perceptions that their participation is voluntary and
is governed by values of reciprocity, non-exploitation and
service of the public good. When these conditions are
not seen to obtain, threats to the social licence for
research may emerge. We propose that care.data failed
to adequately secure a social licence because of:
(i) defects in the warrants of trust provided for care.data,
(ii) the implied rupture in the traditional role,
expectations and duties of general practitioners, and
(iii) uncertainty about the status of care.data as a public
good. The concept of a social licence may be useful in
explaining the speciﬁcs of care.data, and also in
reinforcing the more general lesson for policy-makers
that legal authority does not necessarily command social
legitimacy.
BACKGROUND
Encouraging more and better health-related research
is now ﬁrmly established as a policy goal in
England.1–3 A crucial feature of the current policy
drive is an emphasis on the use of the distinctive
infrastructure of the personal medical records of
individuals registered with the National Health
Service (NHS). Researchers have long argued that,
contrary to the public interest, these records have
remained under-exploited as a research resource.4
Yet the recent launch of care.data—an initiative to
extract data from NHS primary care medical
records in England unless patients have purposefully
opted out, in part to facilitate research—has proved
deeply controversial. Within weeks of the start of a
public information campaign run by NHS England,
public and professional concern had become so
overwhelming that in February 2014 the implemen-
tation of the scheme was suspended for 6 months.5
Our aim in this article is not to assess the rights and
wrongs of care.data—others have already offered
such critiques6—nor to offer an in-depth analysis of
the legal background, but rather to show how the
concept of a social licence7 can help to explain the
challenges faced by care.data.
Although care.data has numerous aims (box 1),
we focus speciﬁcally on its research purposes. We
begin by offering some brief background on the use
and regulation of routine medical data before intro-
ducing the concept of a social licence.
THE USE AND REGULATION OF MEDICAL
RECORDS FOR RESEARCH
Researchers have long relied on access to personal
medical information routinely collected during the
course of patient care in order to conduct studies,
including clinical trials and epidemiological
research. However, the repurposing of routinely
collected data for research is not without risk to
relevant values,8 and measures such as anonymisa-
tion (even when possible) do not solve all ethical,
legal and technical problems; people may, for
example, have religious or moral objections to par-
ticular studies5 or concerns about stigma and
breaches of privacy.
Accordingly, researchers’ access to, and use of,
personal data has traditionally been subject both to
tight controls and to efforts to promote public and
patient conﬁdence in those controls. The Data
Protection Act 1998, which implements the
European Data Protection Directive, has always
recognised ‘medical purposes’ as a legal basis for
processing personal data from medical records,
subject to a proportionality test. While it contains a
‘research exemption’, it does not absolve data con-
trollers completely of their obligations under the
law.9 10 Data protection has been bolstered by the
requirement, introduced in 1999, that each NHS
organisation have a designated senior individual
(known as a Caldicott Guardian) with responsibility
both for the conﬁdentiality of patient information
—which is protected by the common law—and for
enabling appropriate information sharing. These
legal measures also operate alongside guidance and
codes of practice issued and updated regularly by
the professional regulators, by the NHS Research
Governance Framework,11 by a system of research
ethics committees, and by a variety of other
mechanisms.
Nonetheless, access to and secondary use of
medical information for research purposes has con-
tinued to be a fraught and contested activity, prone
to concern over its ethical standing.12 The tensions
were discussed extensively in a 2006 report of the
Academy of Medical Sciences (AMS),4 in a docu-
ment that can be seen as an attempt at advocacy on
the part of a clinical research community that saw
itself as beleaguered and misunderstood. The
report offered multiple examples of the beneﬁts of
research that uses routinely collected personal data,
including its possibilities as a means of answering
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primary research questions, as a prelude to clinical trials, as a
means for disease surveillance, and as a resource for identifying
potential participants in trials or other studies. But such activ-
ities were, the AMS report argued, continually thwarted by the
complexities and frustrations of multiple legal, regulatory and
professional restrictions.
The AMS report13 and others, while accepting the need for
regulation, argued that the regulatory environment for the use
of personal data for health research in England was, by 2006,
not in the public interest: it was disproportionate relative to the
risks and beneﬁts involved and involved multiple overlapping
layers, institutions and actors as well as contested and sometimes
conﬂicting standards and expectations for research governance.
While accepting the broad principle of the need for regulation,
the report suggested that NHS organisations were overly cau-
tious about legal risk in areas of interpretive uncertainty, and
tended to default to a conservative approach. The way the rules
relating to data protection were understood, interpreted and
applied by NHS organisations, research ethics committees and
others was a focus of particular criticism. The overall effect, the
report and others argued, was that NHS organisations were gen-
erally reluctant to share personal information without explicit
consent from patients or anonymisation of data to remove them
from the reach of data protection legislation: the dichotomous
‘consent or anonymise’ approach was the norm.
Yet this was not the only possible approach, nor was it
required by law. Under what was Section 60 of the Health and
Social Care Act (2001) (later Section 251 of the NHS Act
2006), a Patient Information Advisory Group (PIAG), acting on
behalf of the Secretary of State, was allowed to approve process-
ing of patient information without seeking patients’ consent for
research purposes. However, the AMS report criticised the
PIAG’s approach, processes and membership, and its alleged
tendency to stress its role in protecting privacy or conﬁdentiality
‘without equal emphasis on the beneﬁts derived from well-
conducted research’.4 PIAG was argued to suffer from mission
creep, applying a stricter standard of absolute and proven neces-
sity rather than assessing whether applications involved a pro-
portionate and justiﬁable interference in privacy.
Central to the AMS report’s argument for reform was that
PIAG appeared to adopt a more conservative approach than
patients and the public would favour. It claimed strong public
approval and support for research using medical records, on the
grounds that the risks involved were low in comparison with
the likely beneﬁts and in comparison with other forms of
research (such as clinical trials). This claim was in keeping with
the inﬂuential (although not necessarily uncontested) view that
over-emphasis on individual consent fails to balance a broader
range of ethical principles and the argument that people have a
responsibility to participate in research.14 15 The tenor of the
arguments was that the proper solution to the challenges sur-
rounding use of routine medical data for research purposes
might then be one of adjusting the regulatory environment to
accommodate what the public would support.16
A SOCIAL LICENCE FOR RESEARCH INVOLVING MEDICAL
RECORDS?
Based on the reasoning that the public would accept and
endorse a less restrictive approach to the use of medical records
for research purposes than the custodians of the system realised,
the AMS’s clarion call was to ‘be bold’. Although it did not use
the term explicitly, the core of the AMS argument was that the
social licence for the use of medical records for research was
more permissive than the operation of the regulatory environ-
ment allowed.
The concept of a social licence is discussed in two distinct lit-
eratures. One important literature derives from the work of the
sociologist Everett Hughes17 who describes the relationship
between a profession and society in terms of the two concepts
of licence and mandate. For Hughes, licence is granted to
certain occupational groups to carry out particular activities; a
mandate is claimed by members of the group to deﬁne for itself
proper conduct in relation to matters concerned with their
work.7 A second, and mostly distinct, corpus of work on cor-
porate social responsibility describes the concept of the ‘social
licence to operate’ as the expectations of society regarding the
conduct and activities of corporations that go beyond the
requirements of formal regulation.18 Thus, industries with sig-
niﬁcant environmental impact may ﬁnd that operating within
the law but outside the boundaries of social approval can result
in corporate damage—for example, by having a negative impact
on a company’s brand or provoking new and restrictive regula-
tion. The Australian mining industry is often offered as an
example of an industry required to earn a social licence, and
maintain it, by behaving in a trustworthy and responsible way; if
it were otherwise, it would face ongoing challenge and costly
delays and interference in its activities.19
Some analogies have been drawn between a social licence for
the mining of minerals and for the process of data mining.20
Regarding these and similar activities, what the social licence
emphasises is the possible need for those (whether they are
public or private bodies, or speciﬁc occupational groups) under-
taking activities likely to provoke public disquiet to go ‘beyond
compliance’ with legal requirements. We propose that a poorly
informed understanding of the social licence for secondary use
of personal medical data, and a failure to recognise that legal
authority might not be enough to secure the social licence,
seems to have been at the heart of the controversy underlying
care.data.
Legal authority for care.data
The Health and Social Care Act 2012 established the Health
and Social Care Information Centre (HSCIC) as an Executive
Non-Departmental Public Body empowered to obtain patient-
identiﬁable information from general practices. Practices them-
selves were, under their NHS contract, obliged to transfer the
data to HSCIC unless patients explicitly opted out. Using a
Box 1 Aims of care.data
NHS England has described the care.data service as: ‘…a new,
modern data system for the NHS in England. Known as care.
data, its purpose will be to provide timely, accurate information
to citizens, clinicians and commissioners about the treatments
and care provided by the NHS’ (http://www.england.nhs.uk/
wp-content/uploads/2013/05/ces-tech-spec-gp-extract.pdf ).
The aims of the care.data programme are sixfold:
1. To support patients’ choice
2. To advance customer services
3. To promote greater transparency
4. To improve outcomes
5. To increase accountability
6. To drive economic growth by making England the default
location for world-class health services research.
NHS, National Health Service.
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centrally managed General Practice Extraction Service (GPES)
based on commercially supplied software, care.data was
intended to gather data monthly, capturing most routine general
practice consultations. The data would then be made available
in aggregate form to the HSCIC, with six aims (box 1) identi-
ﬁed for their use, including that of driving ‘economic growth by
making England the default location for world-class health ser-
vices research’.
Applications to use the data are to be reviewed by the
HSCIC’s Data Access Advisory Group. If requests to use data
are classiﬁed as sensitive and identiﬁable, researchers are subject
to additional requirements, including that of undergoing scru-
tiny from the Conﬁdentiality Advisory Group of the Health
Research Authority. This group replaced the PIAG and an
interim body (the Ethics and Conﬁdentiality Committee operat-
ing under the National Information Governance Board). It con-
tinues the role of advising on data use for research when
individual consent has not been obtained on the basis of
so-called Section 251 approvals.
Other changes relevant to the creation of care.data included
amendments in 2012 to the NHS Constitution21 to offer a
‘pledge’ to inform English NHS patients about research studies
in which they might be eligible to participate, and also, crucially,
an expectation that patients would be willing to share their
medical information for healthcare planning and for research
purposes. The relevant section—‘Respect, consent and conﬁden-
tiality’ (p. 8)—explains that patients have the right to request
that their information should not be shared but also that such
requests may not be upheld if the public interest is found to out-
weigh the individual case.
Thus was the administrative infrastructure for care.data
created—but not, it seems, the social licence. The amendments
to the Health and Social Care Act 2012 and to the NHS
Constitution seem to have been based on a re-imagining and
re-responsibilisation of patients as active citizens. There has
been an assumption that the implicit social contract underpin-
ning the NHS would mean most patients would be happy to
support sharing of their personal data in the interests of the six
aims of the care.data programme, including economic goals to
be realised through research.
Yet the extent to which conﬁdence in such assumptions was
well-founded was not clear. Previous social science research sug-
gests a nuanced and delicate understanding of societal support
for, and cooperation with, health research is needed.7 It has
found that the public’s support and tolerance for research, and
its associated risks, often depends far more on an often fragile
set of cues about the safety and social good of research partici-
pation, and on institutional and professional credentials, than it
does on the formal architecture of research regulation, or on
rational assessment of the detail of information sheets or other
documents aimed at gaining ‘informed consent’.22 23
Further, most of what is known about patients’ support for
research is based on quite particular examples of research par-
ticipation—often those where patients already have an interest
in a medical condition and where they are asked for quite spe-
ciﬁc consent to a project or programme. Where patients speciﬁc-
ally consent to a particular study or programme of research,
they may (depending on the study) expect the possibility of
some personal beneﬁt, as well as being able to experience sec-
ondary beneﬁts of their consent, such as the ‘warm glow’ asso-
ciated with altruistic behaviour that beneﬁts an identiﬁable
community (eg, of those with a speciﬁc disease).24 The extent
to which the ﬁndings of this body of research about participa-
tion in speciﬁc, relatively well-bounded studies or cohorts by
deﬁned, consenting patients can be generalised to the broader
conception of NHS citizenship implicit in the new policy direc-
tion is not clear.
What is clear is that individuals’ cooperation with speciﬁc
research studies is usually secured through three principal
mechanisms: their expectations about how research is conducted
and regulated; their trust in the institutions and individuals who
recruit them; and their beliefs in the wholesomeness and public
value of the research endeavour. More broadly, the public legit-
imacy and acceptability of health research rests heavily on its
status as a socially valuable enterprise conducted in the service
of the public good.25
There are many reasons to doubt that care.data could reason-
ably assume that the public would automatically confer upon it
the same legitimacy and endorsement as that enjoyed by
research where individual informed consent is sought and clear
information about study aims is provided. For instance, the
mobility of electronic data and the practical difﬁculties of speci-
fying in advance the research questions for which data might be
used or the populations to be studied mean that care.data was in
many ways quite distinct from conventional research projects.
Three threats to the social licence faced by care.data are espe-
cially important in explaining the challenges it faced: (i) defects
in the warrants of trust provided for care.data, (ii) the implied
rupture in the traditional role, expectations and duties of
general practitioners (GPs), and (iii) uncertainty about the status
of care.data as a public good.
WARRANTS OF TRUST
Ensuring that people are aware of how data from medical
records has been or might be used, and the protections that are
in place, might be assumed to be critical to ensuring their conﬁ-
dence that such use is legitimate and well-governed.10 A system-
atic review of public awareness of, and views on consent to, the
secondary use of medical records for health has identiﬁed a gen-
eralised lack of awareness and understanding.26 Yet level of
‘awareness’ itself may not be a reliable guide to people’s faith in
a system. Individuals’ willingness to cooperate with health
research often depends on powerful heuristics rather than
detailed understanding of research governance procedures and
standards.7 Even when they agree to take part in speciﬁc
studies, it is not the detail of consent forms and information
sheets that matters to participants so much as an overall faith in
the legitimacy of the endeavour and a reassurance of protection
from risk.22 23 27 28 Important, too, is a belief that agreeing to
participate in research will not make individuals vulnerable to
risk of harm, exploitation or charges of gullibility.27 This is not
to imply that consent forms and information sheets are of no
value or relevance; on the contrary, they act as ‘symbolic
tokens’,23 as vitally important warrants of the trustworthiness of
the process.22
Thus, a lack of detailed awareness might have mattered little
in the roll-out of care.data had the right warrants of trust been
in place. But the approach adopted did not appear to provide
them. The implied consent model underlying care.data did
allow for patients to opt out, but the process for ensuring that
they were enabled to do so was precarious.29 The practical
delivery of the requirement to ensure patients were aware of
care.data and their right to opt out proved problematic. The
NHS England information leaﬂet about the initiative was
addressed to households rather than individuals and might have
appeared to be unsolicited junk mail.
For those seeking to improve their understanding, the leaﬂet
itself did not appear to be fully informative. Entitled ‘Better
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Information Means Better Care’, it made no explicit reference to
care.data other than to direct those seeking further information
to an NHS website. It did not include an opt-out form. The bene-
ﬁts of information sharing were explained in the patient informa-
tion leaﬂet, but the risks were not.30 HSCIC’s own
acknowledgement that ‘a small risk of re-identiﬁcation due to
small numbers/rare diseases’31 was not conveyed. Questions
about who would access data, for which purposes and on which
terms, were also left unclear, despite evidence showing that the
public wanted more information about how governments and
companies collect, share and use data.32 Additionally, it was not
clear that busy GPs would have the time or sufﬁcient information
to engage in complex discussions with patients wishing to opt
out, nor was any extra resource or support provided for the task,
even for vulnerable groups such as care home residents. The con-
cerns of GPs regarding losing control of patient data during this
process were also not addressed. Further, few opportunities were
available to the public to inﬂuence the direction of policy.33–35
Overall, in contrast to the cues usually available to research
candidates, the warrants of trust provided by care.data appeared
inadequate and were likely to have undermined the social
licence rather than strengthen it. Lack of detail in the informa-
tion sheets was unlikely to have been the direct cause of the
failure to secure the social licence, but it does provide visible
evidence of how the operationalisation of the programme was
founded in poor understanding of what was needed for the
public and professionals to have trust and conﬁdence in it.
Inadequate consultation and engagement meant a failure to take
into account ‘the right things’ and thus secure the social licence.
RUPTURE IN TRADITIONAL EXPECTATIONS
The legitimacy of health research draws heavily and crucially on
people’s trust in organisational and professional credentials,7
including the trust placed in professionals who have a duty of con-
ﬁdentiality36 and relationships developed through continuity of
care and empathy.37 GPs are constrained both by the common law
duty of conﬁdentiality and statutory requirements under the Data
Protection Act 1998 and Human Rights Act 1998 to respect
patient conﬁdences and to process personal data or disclose conﬁ-
dential information only within clearly deﬁned parameters.
However, in neither legal regime is the protection of privacy abso-
lute. A 2013 review of the system of information governance in
health and social care services clariﬁed, for example, that legally
patients do not own their data.9 Notwithstanding, what is legally
permissible and what is socially acceptable do not necessarily coin-
cide. For some, care.data represents a signiﬁcant and unwelcome
alteration to traditional understandings of the private and conﬁ-
dential nature of the relationship between GP and patient.
Some accounts argue that routine monthly extraction of elec-
tronic individual level patient data from GP records represents a
step-change in terms of the level of intrusion into patients’
private lives, to the extent that it has been suggested that it
erodes the fundamental right to respect for private life offered
by the Human Rights Act. Concerns have been expressed that
patients may not wish intimate details of their medical records
to be accessible to those outside of their ‘circle of care’,38 and
might decline to trust and conﬁde in their healthcare providers
if they know that their information will be shared.39 The law
has long recognised the importance of protecting this trust for
both the private and public interests that it serves (see, for
example, the cases of X v Y (1988) 2 ALL ER 648 and also
Campbell v Mirror Group Newspapers (2004) UKHL 22).
These concerns are linked in part to the advances in techno-
logical capability associated with ‘big data’32 which offer the
opportunity to address novel research questions40 but also gen-
erates new ethical dilemmas in relation to re-identiﬁcation of
individuals14 41–43 or losses of data and other intrusions asso-
ciated with risks to anonymity and privacy. Again, the extent to
which the social licence for these potentially profound altera-
tions to the nature of the doctor–patient relationship was
secured for care.data is in question.
STATUS OF CARE.DATA AS A PUBLIC GOOD
Values of reciprocity and fairness underpin the legitimacy of
health research: if people participate voluntarily, they expect
that their contribution will be used to improve the care of
others, and that their good faith will not be exploited.23 24
Much depends, therefore, on the extent to which uses of per-
sonal data are seen as serving the public interest and conducted
by those with a public interest orientation. Yet neither of these
features of the social licence seems to have been fully addressed
for care.data.
The ‘public regime of justiﬁcation’36 that was provided for
care.data stressed its beneﬁts at a national rather than an individ-
ual level. Of the six aims of care.data (box 1), the ﬁrst ﬁve are
rooted in the use of data to improve quality and delivery of care
and the governance of healthcare, with the recommendations of
Sir Robert Francis arising from his damning report on Mid
Staffordshire NHS Trust44 invoked to supply part of the motiv-
ation. However, there are indications that members of the
public expect to see beneﬁts of such data use made explicit.26
The sixth aim of care.data refers to research, but in a way that
links it explicitly to economic growth.
The multiplicity of aims towards which care.data is directed,
and the linking of care.data and research to the so-called ‘health
and wealth’ agenda, may be an unfamiliar rationale for citizens
used to a public service model of healthcare.45 Patients may mis-
trust commercial interests, especially where these might be per-
ceived as proﬁteering or resulting in excessive proﬁt26 32 35 46–48
or where patients have concerns about the extent to which risks
and beneﬁts are evenly distributed and whether their contribu-
tions to research will be reciprocated by a contribution to the
public good. The persistent problem of non-publication of study
results is just one element of how non-reciprocation may mani-
fest.49 Other concerns may be linked to questions of who will be
able to access care.data for which purposes with which risks, how
the credentials of bona ﬁde researchers can be established, and
what mandate commercial organisations will have to use data
that originated from private consultations between patients and
their GPs.
The complexity is ampliﬁed by the institutional fragmentation
of the NHS in England, which is no longer a single unitary
public sector entity. Transfer of information ‘within the NHS’ in
practice means transfer between entities with distinct legal
status. This takes place in a complex framework of statutory
provisions and legal contracts, and it increasingly occurs with
those who are private contractors of services to the NHS or
may operate outside the NHS entirely. Concerns about insur-
ance companies and others having access to personal data5
suggest that considerable further dialogue between the public,
affected stakeholders such as GPs, and policy makers is required
before a social licence can be said to be in place for care.data.
CONCLUSIONS
The concept of a social licence offers insight into why the
implementation of care.data, an initiative to extract data from
routine general practice consultations for use in research and
other activities, has met with concern and controversy. Although
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the infrastructure was in place, the activities were perfectly
lawful, and a case had been made for the possible beneﬁts that
might be generated, the experience of care.data starkly exposes
an enduring truism about the limits of law: legal authority does
not necessarily command social legitimacy. A parliamentary
majority may allow legislation to be passed, but that does not
equate to a societal seal of approval or to securing the trust and
conﬁdence of patients, citizens, healthcare professionals and
researchers. Securing a social licence may require something
other than a legal mandate.
Although England has remained ﬁrmly on the legislative path,
different solutions to the same challenges relating to the use of
personal medical information have been found north of the
border.50 Rather than legislative change, actors operating within
the existing legal frameworks have worked together under the
Scottish Health Informatics Programme (SHIP) to develop
mechanisms of principled proportionate governance—building
on public engagement exercises—to deliver responsive, risk-
based approaches to data linkage for health research. Consent,
anonymisation and authorisation are all available as governance
tools to be deployed, as appropriate, in any given data linkage
proposal after an assessment of the risks and tolerances
involved.51
As the Scottish example shows,51 this does not mean that
unanimous social consensus is required for all developments.
Rather, a social licence for research will require, as a minimum,
that certain conditions of social engagement have been
respected. Genuine dialogic engagement that might result in a
broad licence must be distinguished from more narrowly
focused public relations exercises that seek to ‘capture’ the
public, that is, to persuade the public of the legitimacy of deci-
sions already taken by experts,33 35 and from simple ‘awareness-
raising’ information exercises. While legitimate disagreement is
inevitable, if a social licence is to be maintained, both the ﬁnal
result and process used to achieve that result must be one which
reasonable citizens can at least recognise as defensible on the
grounds that it reﬂects common social values and goals.
Trust and conﬁdence in research governance or the ‘social
licence for research’ depends upon ideas about the public good
that are not straightforwardly synonymous with the aim of
increasing the UK’s gross domestic product. What patients care
about as patients cannot be equated with what patients care
about as citizens who are part of a much wider social endeav-
our. If care.data is to succeed, patients need to have the conﬁ-
dence that their medical records will be held securely,
anonymised appropriately, and that secondary use of this per-
sonal data is in the public interest: the conditions of the social
licence need to be respected in ways that go beyond compliance
laid down in a legal framework. Necessary—and hopefully sufﬁ-
cient—conditions for social licence include: (i) reciprocity,
which must begin with sound two-way communication, (ii) non-
exploitation, which must exclude the spectre of disempower-
ment, and (iii) service of the public good, which need not
exclude a wealth agenda so long as there is conﬁdence that
research governance and information governance systems can
hold researchers, and others with custodial responsibility for
medical information, to account.
Twitter Follow Mary DixonWoods at @MaryDixonWoods
Contributors PC conceived of the project and drafted the article. MD-W and GL
reviewed several drafts, suggested new literature and commented on and revised the
structure and intellectual content.
Funding Graeme Laurie holds a Wellcome Trust Senior Investigator Award
(WT103360MA) and is Co-Investigator on the 10-funder Farr Institute of Health
Informatics Research (MRC Grant No: MR/K007017/1, MR/K006525/1, MR/
K006584/1 and MR/K006665/1). Professor Mary Dixon-Woods holds a Senior
Investigator Award from the Wellcome Trust (WT097899) that has supported this
work.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1 Department of Health. Best research for best health: a new national health research
strategy. The NHS contribution to health research in England. London: Department
of Health, 2006.
2 Liddell A, Ayling M, Reid G. Innovation, health and wealth accelerating adoption
and diffusion in the NHS. Department of Health, 2011.
3 HM Treasury and Department for Business Innovation and Skills. The plan for
growth. Crown Copyright. 2011.
4 The Academy of Medical Sciences. Personal data for public good: using health
information in medical research. London: The Academy of Medical Sciences, 2006.
5 Taylor M. Information governance as a force for good? Lessons to be learnt from
care.data. Script Ed 2014;11(1):1–8.
6 Pollock AM, Roderick P. Trust in the time of markets: protecting patient information.
Lancet 2014;383(9928):1523–4.
7 Dixon-Woods M, Ashcroft RE. Regulation and the social licence for medical
research. Med Health Care Philos 2008;11:381–91.
8 Clark S, Weale A. Information governance in health. Nufﬁeld Trust, 2011.
9 Caldicott F. Information: to share or not to share? The Information Governance
Review. Crown Copyright. London: Williams Lea for the Department of Health,
2013.
10 Taylor MJ. Health research, data protection, and the public interest in notiﬁcation.
Med Law Rev 2011;19(2):267–303.
11 Department of Health. Research governance framework for health and social care.
2nd edn. https://www.gov.uk/government/uploads/system/uploads/attachment_data/
ﬁle/139565/dh_4122427.pdf (accessed 24 Oct 2014).
12 Doyal L, Tobias JS. Informed consent in medical research. London: BMJ Books,
2001.
13 Walley T. Using personal health information in medical research. BMJ 2006;332
(7534):130–1.
14 McHale J. Reforming the regulation of health research in England and Wales: new
challenges: new pitfalls. J Med Law Ethics 2013;1(1):23–42.
15 Harris J. Scientiﬁc research is a moral duty. J Med Ethics 2005;31(4):242–8.
16 The Academy of Medical Sciences. A new pathway for the regulation and
governance of health research. The Academy of Medical Sciences, 2011. http://
www.acmedsci.ac.uk/p99puid209.html
17 Hughes EC. Men and their work. Glencoe, Illinois: Free Press, 1958.
18 Gunningham N, Robert A, Thornton D. Social license and environmental protection:
why businesses go beyond compliance. Law Soc Inq 2004;29(2):307–41.
19 Allen G. Public affairs and mining in Australia–a rescued license to operate. J Public
Aff 2011;11(4):382–6.
20 Rooney D, Leach J, Ashworth P. Doing the social in social license. Soc Epistemol
2014;28(3–4):209–18.
21 Department of Health, London. NHS Constitution—the NHS belongs to us all.
2012.
22 Armstrong N, Dixon-Woods M, Thomas A, et al. Do informed consent documents
for cancer trials do what they should? A study of manifest and latent functions.
Sociol Health Illn 2012;34(8):1230–45.
23 Dixon-Woods M, Ashcroft RE, Jackson CJ, et al. Beyond “misunderstanding”:
written information and decisions about taking part in a genetic epidemiology
study. Soc Sci Med 2007;65(11):2212–22.
24 Dixon-Woods M, Tarrant C. Why do people cooperate with medical research?
Findings from three studies. Soc Sci Med 2009;68(12):2215–22.
25 Dixon-Woods M, Wilson D, Jackson C, et al. Human tissue and ‘the public’: the
case of childhood cancer tumour banking. BioSocieties 2008;3(1):57–80.
26 Hill EM, Turner EL, Martin RM, et al. “Let’s get the best quality research we can”:
public awareness and acceptance of consent to use existing data in health research: a
systematic review and qualitative study. BMC Med Res Methodol 2013;13(1):1–10.
27 Kenyon S, Dixon-Woods M, Jackson CJ, et al. Participating in a trial in a critical
situation: a qualitative study in pregnancy. Qual Saf Health Care 2006;15
(2):98–101.
28 Dixon-Woods M, Tarrant C, Jackson CJ, et al. Providing the results of research to
participants: a mixed-method study of the beneﬁts and challenges of a consultative
approach. Clin Trials 2011;8(3):330–41.
29 Callaway E. UK push to open up patients’ data. Nature 2013;502:283.
Carter P, et al. J Med Ethics 2015;0:1–6. doi:10.1136/medethics-2014-102374 5
Current controversy
group.bmj.com on January 26, 2015 - Published by http://jme.bmj.com/Downloaded from 
30 NHS England. Better information means better care, 2014.
31 Health and Social Care Information Centre. General Practice Extraction Service
(GPES) customer requirement summary NIC-178106-MLSWX. Health and Social
Care Information Centre, 2012.
32 Sciencewise. Big data: public views on the collection, sharing and use of personal
data by government and companies. Sciencewise, 2014. http://www.
sciencewise-erc.org.uk/cms/big-data
33 Raman S, Mohr A. A social licence for science: capturing the public or
co-constructing research? Soc Epistemol 2014;28(3–4):258–76.
34 Garrety K, McLoughlin I, Wilson R, et al. National electronic health records and the
digital disruption of moral orders. Soc Sci Med 2013;101(0):70–7.
35 Davidson S, McLean C, Treanor S, et al. Public acceptability of data sharing
between the public, private and third sectors for research purposes. Scottish
Government Social Research, 2013. http://www.scotland.gov.uk/socialresearch
36 Wellcome Trust. Towards consensus for best practice: use of patient records from
general practice for research. London, 2009.
37 Stone MA, Redsell SA, Ling JT, et al. Sharing patient data: competing demands of
privacy, trust and research in primary care. Br J Gen Pract 2005;55(519):783–9.
38 Perera G, Holbrook A, Thabane L, et al. Views on health information sharing and
privacy from primary care practices using electronic medical records. Int J Med Inf
2011;80(2):94–101.
39 medConﬁdential. What’s the story? 2013. http://medconﬁdential.org/
whats-the-story/ (accessed 7 Nov 2013).
40 Murtagh M, Thorisson G, Wallace S, et al. Navigating the perfect [data] storm.
Norsk Epidemiol 2012;21(2):203–9.
41 Brown I, Brown L, Korff D. Using NHS patient data for research without consent.
Law Innov Technol 2010;2(2):219–58.
42 Thomas R, Walport M. Data sharing review. Copyright Richard Thomas and Mark
Walport, 2008.
43 Ohm P. Broken promises of privacy: responding to the surprising failure of
anonymization. UCLA Law Rev 2010;57:1701.
44 Francis R. Report of the mid Staffordshire NHS Foundation Trust public inquiry.
London: Stationery Ofﬁce, 2013. http://cdn.midstaffspublicinquiry.com/sites/default/
ﬁles/report/Executive%20summary.pdf
45 Macfarlane A, Pollock A. Opting out of care.data is not the answer. 2014. http://
www.statslife.org.uk/opinion/1210-opting-out-of-care-data-is-not-the-answer
46 Haddow G, Laurie G, Cunningham-Burley S, et al. Tackling community concerns
about commercialisation and genetic research: a modest interdisciplinary proposal.
Soc Sci Med 2007;64:272–82.
47 Ipsos MORI. Public Dialogue Workshops Report prepared for the Health Research
Authority. Ipsos MORI, 2013.
48 Hunn A. Survey of the general public: attitudes towards health research. Health
Research Authority, 2013.
49 Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results
published. BMJ 2013;346:f105.
50 McCartney M. Care.data: why are Scotland and Wales doing it differently? BMJ
2014;348:g1702.
51 Sethi N, Laurie GT. Delivering proportionate governance in the era of
eHealth: making linkage and privacy work together. Med Law Int 2013;13
(2–3):168–204.
6 Carter P, et al. J Med Ethics 2015;0:1–6. doi:10.1136/medethics-2014-102374
Current controversy
group.bmj.com on January 26, 2015 - Published by http://jme.bmj.com/Downloaded from 
 ran into troublecare.data
The social licence for research: why 
Pam Carter, Graeme T Laurie and Mary Dixon-Woods
 published online January 23, 2015J Med Ethics 
 http://jme.bmj.com/content/early/2015/01/23/medethics-2014-102374
Updated information and services can be found at: 
These include:
References
 #BIBL
http://jme.bmj.com/content/early/2015/01/23/medethics-2014-102374
This article cites 27 articles, 8 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (85)General practice / family medicine
 (55)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 26, 2015 - Published by http://jme.bmj.com/Downloaded from 
